Status:

TERMINATED

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Lead Sponsor:

Cardurion Pharmaceuticals, Inc.

Conditions:

CPVT1

Heart Defects, Congenital

Eligibility:

All Genders

18-99 years

Phase:

PHASE2

Brief Summary

This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodyn...

Eligibility Criteria

Inclusion

  • Males or Females ≥18 years of age, at screening.
  • Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at screening.
  • The participant can perform an EST during which frequent premature ventricular contraction (PVCs) (≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator.
  • Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to screening.
  • Adhere to all contraceptive criteria.

Exclusion

  • Clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
  • History of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of screening.
  • History of malignancy within the past 5 years at screening (except successfully treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ).
  • Female participant that is pregnant or lactating/ breastfeeding, or has plans to do so during the study or within 3 months following last dose of study drug.
  • Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.

Key Trial Info

Start Date :

November 7 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 31 2025

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT06005428

Start Date

November 7 2023

End Date

May 31 2025

Last Update

July 14 2025

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

2

Cleveland Clinic Children's Hospital

Cleveland, Ohio, United States, 44195

3

Baylor College of Medicine

Houston, Texas, United States, 77030

4

Stollery Children's Hospital University of Alberta

Edmonton, Alberta, Canada, T6G 2R7

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | DecenTrialz